Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique

[1]  P. Easterbrook,et al.  Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial , 2017, The lancet. HIV.

[2]  P. Kaleebu,et al.  Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa , 2017, The Journal of antimicrobial chemotherapy.

[3]  T. F. Rinke de Wit,et al.  Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. , 2016, The Journal of antimicrobial chemotherapy.

[4]  M. Peeters,et al.  Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa. , 2016, AIDS research and human retroviruses.

[5]  Lei Zhang,et al.  Projecting the epidemiological effect, cost-effectiveness and transmission of HIV drug resistance in Vietnam associated with viral load monitoring strategies. , 2016, The Journal of antimicrobial chemotherapy.

[6]  R. Paredes,et al.  Determinants of virological failure and antiretroviral drug resistance in Mozambique. , 2015, The Journal of antimicrobial chemotherapy.

[7]  A. Tanuri,et al.  Trends in Prevalence of HIV-1 Drug Resistance in a Public Clinic in Maputo, Mozambique , 2015, PloS one.

[8]  K. Ruxrungtham,et al.  Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis. , 2015, The lancet. HIV.

[9]  J. Schapiro,et al.  Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries. , 2013, The Journal of infectious diseases.

[10]  J. Mellors,et al.  Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  T. F. Rinke de Wit,et al.  Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. , 2012, The Journal of infectious diseases.

[12]  A. De Luca,et al.  Prognostic Value of Virological and Immunological Responses After 6 Months of Antiretroviral Treatment in Adults With HIV-1 Infection in Sub-Saharan Africa , 2012, Journal of acquired immune deficiency syndromes.

[13]  W. Stevens,et al.  Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa. , 2012, AIDS research and human retroviruses.

[14]  Beth Chaplin,et al.  Immunologic criteria are poor predictors of virologic outcome: implications for HIV treatment monitoring in resource-limited settings. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  T. F. Rinke de Wit,et al.  Unnecessary Antiretroviral Treatment Switches and Accumulation of HIV Resistance Mutations; Two Arguments for Viral Load Monitoring in Africa , 2011, Journal of acquired immune deficiency syndromes.

[16]  R. Kaiser,et al.  Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. , 2011, The Journal of antimicrobial chemotherapy.

[17]  D. Pillay,et al.  Drug Resistance in Human Immunodeficiency Virus Type-1 Infected Zambian Children Using Adult Fixed Dose Combination Stavudine, Lamivudine, and Nevirapine , 2010, The Pediatric infectious disease journal.